

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for August 2024

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Dr. Reddy's Laboratories Canada Inc.	Reddy-Everolimus	Afinitor	EVEROLIMUS	2.5 mg	tablet	02532409
Dr. Reddy's Laboratories Canada Inc.	Reddy-Everolimus	Afinitor	EVEROLIMUS	5 mg	tablet	02532417
Dr. Reddy's Laboratories Canada Inc.	Reddy-Everolimus	Afinitor	EVEROLIMUS	10 mg	tablet	02532433
Jamp Pharma Corporation	Jamp Gatifloxacin	Zymar	GATIFLOXACIN	0.3% w/v	ophthalmic solution	02533235
Mint Pharmaceuticals Inc.	Mint-Metformin XR	Glumetza	METFORMIN HCl	500 mg	ER tablet	02547309

Mint Pharmaceuticals Inc.	Mint-Metformin XR	Glumetza	METFORMIN HCl	1000 mg	ER tablet	02547317
---------------------------------	----------------------	----------	---------------	---------	-----------	----------